-
公开(公告)号：US20070032525A1
公开(公告)日：2007-02-08
申请号：US10511174
申请日：2003-04-16
申请人： Yoshiyuki Matsumoto , Minoru Imai , Yoshiyuki Sawai , Susumu Takeuchi , Akinobu Nakanishi , Kunio Minamizono , Tomonori Yokoyama
发明人： Yoshiyuki Matsumoto , Minoru Imai , Yoshiyuki Sawai , Susumu Takeuchi , Akinobu Nakanishi , Kunio Minamizono , Tomonori Yokoyama
IPC分类号： A61K31/454 , C07D487/02
CPC分类号： C07D401/12 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/517 , A61K31/5377 , A61K31/5415 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/04
摘要： The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.
摘要翻译： 本发明提供具有抑制靶细胞CCR3拮抗剂上CCR3配体与CCR3结合的活性的低分子化合物。 本发明还提供由下式（I）表示的化合物，其药学上可接受的酸加合物或其药学上可接受的C 1 -C 6烷基加合物，以及药物组合物 包括它们作为有效成分，其可用于治疗或预防与CCR3相关的疾病，例如哮喘和过敏性鼻炎。
-
公开(公告)号：US07517875B2
公开(公告)日：2009-04-14
申请号：US10511174
申请日：2003-04-16
申请人： Yoshiyuki Matsumoto , Minoru Imai , Yoshiyuki Sawai , Susumu Takeuchi , Akinobu Nakanishi , Kunio Minamizono , Tomonori Yokoyama
发明人： Yoshiyuki Matsumoto , Minoru Imai , Yoshiyuki Sawai , Susumu Takeuchi , Akinobu Nakanishi , Kunio Minamizono , Tomonori Yokoyama
IPC分类号： C07D487/04 , C07D403/12 , C07D403/14 , A61K31/4523 , A61K31/454 , A61P11/06
CPC分类号： C07D401/12 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/517 , A61K31/5377 , A61K31/5415 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/04
摘要： The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.
摘要翻译： 本发明提供具有抑制靶细胞CCR3拮抗剂上CCR3配体与CCR3结合的活性的低分子化合物。 本发明还提供由下式（I）表示的化合物，其药学上可接受的酸加合物或其药学上可接受的C1-C6烷基加合物，以及包含它们作为有效成分的药物组合物，其可用于治疗或预防相关疾病 与CCR3，如哮喘和过敏性鼻炎。
-
公开(公告)号：US07524841B2
公开(公告)日：2009-04-28
申请号：US10512339
申请日：2003-04-16
申请人： Yoshiyuki Matsumoto , Minoru Imai , Yoshiyuki Sawai , Susumu Takeuchi , Akinobu Nakanishi , Kunio Minamizono , Tomonori Yokoyama
发明人： Yoshiyuki Matsumoto , Minoru Imai , Yoshiyuki Sawai , Susumu Takeuchi , Akinobu Nakanishi , Kunio Minamizono , Tomonori Yokoyama
IPC分类号： C07D487/04 , C07D403/12 , C07D403/14 , A61K31/4523 , A61K31/454 , A61P11/06
CPC分类号： C07D401/12 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/517
摘要： The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides 4,4-(disubstituted)piperidine derivatives represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.
摘要翻译： 本发明提供具有抑制靶细胞CCR3拮抗剂上CCR3配体与CCR3结合的活性的低分子化合物。 本发明还提供由下式（I）表示的4,4-（二取代的）哌啶衍生物，其药学上可接受的酸加合物或其药学上可接受的C1-C6烷基加合物，以及包含它们作为有效成分的药物组合物， 可用于治疗或预防与CCR3相关的疾病，如哮喘和过敏性鼻炎。
-
4.发明申请公开(公告)号：US20070037851A1
公开(公告)日：2007-02-15
申请号：US10512339
申请日：2003-04-16
申请人： Yoshiyuki Matsumoto , Minoru Imai , Yoshiyuki Sawai , Susumu Takeuchi , Akinobu Nakanishi , Kunio Minamizono , Tomonori Yokoyama
发明人： Yoshiyuki Matsumoto , Minoru Imai , Yoshiyuki Sawai , Susumu Takeuchi , Akinobu Nakanishi , Kunio Minamizono , Tomonori Yokoyama
IPC分类号： C07D487/02 , A61K31/454
CPC分类号： C07D401/12 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/517
摘要： The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides 4,4-(disubstituted)piperidine derivatives represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.
摘要翻译： 本发明提供具有抑制靶细胞CCR3拮抗剂上CCR3配体与CCR3结合的活性的低分子化合物。 本发明还提供由下式（I）表示的4,4-（二取代的）哌啶衍生物，其药学上可接受的酸加成物或药学上可接受的C 1 -C 6烷基 其加合物，以及包含它们作为有效成分的药物组合物，其可用于治疗或预防与CCR3相关的疾病，例如哮喘和过敏性鼻炎。
-
公开(公告)号：US07576117B1
公开(公告)日：2009-08-18
申请号：US10031698
申请日：2000-08-04
申请人： Tatsuki Shiota , Masaki Sudoh , Tomonori Yokoyama , Yumiko Muroga , Takashi Kamimura , Akinobu Nakanishi
发明人： Tatsuki Shiota , Masaki Sudoh , Tomonori Yokoyama , Yumiko Muroga , Takashi Kamimura , Akinobu Nakanishi
CPC分类号： C07D207/14 , A61K31/40 , A61K31/445
摘要： A medicine containing, as an active ingredient, a cyclic amine derivative represented by the following formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1 to C6 alkyl addition salt thereof. The medicine has an action for treating or preventing diseases in which CCR3 participates, such as asthma and allergic rhinitis.
摘要翻译： 含有下式（I）表示的环状胺衍生物，其药学上可接受的酸加成盐或其药学上可接受的C1〜C6烷基加成盐作为有效成分的药物。 该药物具有治疗或预防CCR3参与疾病的作用，如哮喘和过敏性鼻炎。
-
公开(公告)号：US20100094026A1
公开(公告)日：2010-04-15
申请号：US12092208
申请日：2006-08-11
IPC分类号： A61K31/35 , C07D407/12 , G01N33/566
CPC分类号： G01N33/6893 , G01N2500/00 , G01N2800/24
摘要： The present invention provides a method of screening for a compound useful for treatment of an allergic disease by identifying a molecule targeted by Intal upon exertion of its efficacy as an anti-allergic agent (hereinafter referred as a target) and using the target, as well as a new type of anti-allergic agent comprising a compound obtainable by the screening as an active ingredient for treatment of an allergic disease.
摘要翻译： 本发明提供一种筛选用于治疗过敏性疾病的化合物的方法，其通过鉴定作为抗过敏剂（以下称为靶标）的功效的Intal作为靶标的分子，以及使用该靶标 作为新型的抗过敏剂，其包含通过筛选获得的化合物作为治疗过敏性疾病的活性成分。
-
公开(公告)号：US20090239916A1
公开(公告)日：2009-09-24
申请号：US11569555
申请日：2005-05-26
IPC分类号： A61K31/428 , G01N33/53 , C12N9/04 , G01N33/68 , C07D311/22 , C07D277/68 , A61K31/352 , A61P29/00
CPC分类号： G01N33/6893 , A61K31/352 , A61K31/428 , C07D277/68 , C07D311/24 , G01N2500/00 , G01N2800/24
摘要： The present invention provides a pharmaceutical composition comprising as an active ingredient a compound that specifically binds to MFP-2 or a functional fragment thereof and a screening method for the compound; the compound and a pharmaceutical composition comprising the same are highly useful as anti-inflammatory agents and anti-allergic agents.
摘要翻译： 本发明提供一种药物组合物，其包含与MFP-2或其功能片段特异性结合的化合物作为活性成分和该化合物的筛选方法; 该化合物和包含该化合物的药物组合物作为抗炎剂和抗过敏剂是非常有用的。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.04 秒)
